If you wish to get in contact with Celixir please submit an enquiry or give us a call.
Our pivotal position in the rapidly evolving regenerative medicine field is supported by a group of leading investors.
Our continued focus on innovation is the key to unlocking the potential of regenerative medicine.
Professor Sir Martin Evans is the co-founder of Celixir.
In 1981, he isolated the first embryonic stem cells.
Ajan Reginald founded Celixir with Professor Sir Martin Evans in 2009 and has served as the company’s Chief Executive Officer since inception.
Sabena Sultan is the Global Head of Research at Celixir. She assumed the role in 2011 and has lead R&D from Celixir’s formation.
Global Head of Discovery Science & Intellectual Property
Lee Chapman is our Global Head of Discovery Science and Intellectual Property.
On the back of extensive research, innovation and partnerships we've become thought leaders.
Getting to work on finding solutions for medical issues that impact the entire globe.
Our researchers are committed to indepth R&A to identify new opportunities to treat ill health.
Cardiovascular disease (CVD), in all of its forms, is the number one killer in the UK, Europe and the US. More often than not, it has long-term effects, including an enlarged, damaged and less efficient Read more…
Where We Are With Stem Cell Research Celixir’s latest research and development – follow Celixir on Twitter Our bodies are made up of different types of cells, but out of all of them, stem cells Read more…
As one of the leading companies invested in stem cell research, Celixir is instrumental in researching and pioneering new and innovative ways to use stem cells, in order to advance medicine, in particular, patient care. Read more…